Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Revenue (2020 - 2025)

Historic Revenue for Fennec Pharmaceuticals (FENC) over the last 6 years, with Q3 2025 value amounting to $12.5 million.

  • Fennec Pharmaceuticals' Revenue rose 7869.23% to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.8 million, marking a year-over-year decrease of 2139.5%. This contributed to the annual value of $47.5 million for FY2024, which is 12368.72% up from last year.
  • As of Q3 2025, Fennec Pharmaceuticals' Revenue stood at $12.5 million, which was up 7869.23% from $9.7 million recorded in Q2 2025.
  • Fennec Pharmaceuticals' Revenue's 5-year high stood at $25.4 million during Q1 2024, with a 5-year trough of -$914000.0 in Q4 2022.
  • Moreover, its 5-year median value for Revenue was $6.5 million (2023), whereas its average is $5.8 million.
  • Its Revenue has fluctuated over the past 5 years, first tumbled by 53333.33% in 2022, then surged by 593333.33% in 2023.
  • Fennec Pharmaceuticals' Revenue (Quarter) stood at -$55000.0 in 2021, then tumbled by 1561.82% to -$914000.0 in 2022, then skyrocketed by 1165.1% to $9.7 million in 2023, then fell by 18.59% to $7.9 million in 2024, then surged by 57.25% to $12.5 million in 2025.
  • Its Revenue stands at $12.5 million for Q3 2025, versus $9.7 million for Q2 2025 and $8.8 million for Q1 2025.